MONDAY, Oct. 28, 2024 -- Empagliflozin continues to offer cardiorenal benefits for up to 12 months after discontinuation among patients with chronic...

MONDAY, Oct. 28, 2024 -- From 2010 to 2023, there was an increase in prescribing of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and sodium...

One of the changes the new government wants is to make a shift from hospital to prevention. The case for investment into osteoporosis treatment is all...

One of the changes the new government wants is to make a shift from hospital to prevention. The case for investment into osteoporosis treatment is all...

Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is...

A new study from the MD Anderson Cancer Center reveals that quitting smoking within six months of a cancer diagnosis can significantly improve...

From November 1, 2024, Indian Railways is implementing a new 60-day Advance Reservation Period for train ticket bookings, down from the previous 120...

Fat-Derived cellular therapy offers a promising new approach for diabetes, using cells from body fat to improve insulin function and potentially...

Contrary to concerns, GLP-1RA medications don't appear to elevate AKI risk in patients undergoing cancer treatment.

Diabetes drug canagliflozin benefits patients of all ages. While SGLT2 inhibitors are known to reduce the risk of heart and kidney problems in...